

Christer Sundström

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6300525/publications.pdf>

Version: 2024-02-01

80
papers

6,251
citations

218677

26
h-index

79698

73
g-index

80
all docs

80
docs citations

80
times ranked

5688
citing authors

#	ARTICLE	IF	CITATIONS
1	Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. <i>Blood Advances</i> , 2022, 6, 152-164.	5.2	11
2	Pre-treatment health-related quality of life parameters have prognostic impact in patients >65 years with newly diagnosed mantle cell lymphoma: The Nordic Lymphoma Group MCL4 (LENA-BERIT) experience. <i>Hematological Oncology</i> , 2022, 40, 23-31.	1.7	1
3	Expression of PD-1, PD-L1 and PD-L2 in Lymphomas in Patients with Pre-Existing Rheumatic Diseases: A Possible Association with High Rheumatoid Arthritis Disease Activity. <i>Cancers</i> , 2022, 14, 1509.	3.7	3
4	Loss of function mutations of <i>BCOR</i> in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1080-1090.	1.3	2
5	Outcome in PCNSL patients and its association with PD-L1+ leukocytes in the tumor microenvironment. <i>Acta Oncologica</i> , 2022, 61, 824-829.	1.8	0
6	Lymphoma risks in patients with rheumatoid arthritis treated with biological drugs: a Swedish cohort study of risks by time, drug and lymphoma subtype. <i>Rheumatology</i> , 2021, 60, 809-819.	1.9	21
7	PD-L1 and IDO1 are potential targets for treatment in patients with primary diffuse large B-cell lymphoma of the CNS. <i>Acta Oncologica</i> , 2021, 60, 531-538.	1.8	10
8	Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets. <i>Blood Advances</i> , 2021, 5, 900-912.	5.2	30
9	Patients with autoimmune diseases have an altered activity of the PD-1 pathway and proportions of Epstein-Barr virus infected cells in benign lymphadenopathies. <i>Immunobiology</i> , 2021, 226, 152069.	1.9	1
10	Prior antithymocyte globulin therapy and survival in post-transplant lymphoproliferative disorders. <i>Acta Oncologica</i> , 2021, 60, 771-778.	1.8	2
11	p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma. <i>British Journal of Haematology</i> , 2020, 191, 796-805.	2.5	31
12	Lymphocyte predominant cells detect <i>Moraxella catarrhalis</i> -derived antigens in nodular lymphocyte-predominant Hodgkin lymphoma. <i>Nature Communications</i> , 2020, 11, 2465.	12.8	31
13	CD30 expression and survival in posttransplant lymphoproliferative disorders. <i>Acta Oncologica</i> , 2020, 59, 673-680.	1.8	11
14	Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. <i>British Journal of Haematology</i> , 2020, 189, 707-717.	2.5	13
15	Expression of PD-1, PD-L1, and PD-L2 in posttransplant lymphoproliferative disorder after solid organ transplantation. <i>Leukemia and Lymphoma</i> , 2019, 60, 376-384.	1.3	31
16	Malignant lymphoma in granulomatosis with polyangiitis: subtypes, clinical characteristics and prognosis. <i>Acta Oncologica</i> , 2019, 58, 1655-1659.	1.8	2
17	High tumour plasma cell infiltration reflects an important microenvironmental component in classic Hodgkin lymphoma linked to presence of B-symptoms. <i>British Journal of Haematology</i> , 2019, 184, 192-201.	2.5	19
18	U-CAN: a prospective longitudinal collection of biomaterials and clinical information from adult cancer patients in Sweden. <i>Acta Oncologica</i> , 2018, 57, 187-194.	1.8	52

#	ARTICLE	IF	CITATIONS
19	Final Analysis of the Front-Line Phase III Randomized ACT-1 Trial in Younger Patients with Systemic Peripheral T-Cell Lymphoma Treated with CHOP Chemotherapy with or without Alemtuzumab and Consolidated By Autologous Hematopoietic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 998-998.	1.4	19
20	Expression of possible targets for new proteasome inhibitors in diffuse large B-cell lymphoma. <i>European Journal of Haematology</i> , 2017, 98, 52-56.	2.2	7
21	Population-based experience on primary central nervous system lymphoma 2000-2012: the incidence is increasing. <i>Acta Oncologica</i> , 2017, 56, 599-607.	1.8	27
22	Numerous Ontogenetic Roads to Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2017, 187, 1454-1458.	3.8	11
23	TET2 mutations in B cells of patients affected by angioimmunoblastic T-cell lymphoma. <i>Journal of Pathology</i> , 2017, 242, 129-133.	4.5	52
24	Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and Tj ETQq 0 0 0 rBT /Overlock 10 Tj 428-435.	2.0	56
25	The Impact of Upfront Autologous Transplant on the Survival of Adult Patients with ALCL and PTCL-NOS According to Their ALK, DUSP22 and TP63 Gene Rearrangement Status - a Joined Nordic Lymphoma Group and Mayo Clinic Analysis. <i>Blood</i> , 2017, 130, 822-822.	1.4	9
26	Lenalidomide-bendamustine-rituximab in patients older than 65 years with untreated mantle cell lymphoma. <i>Blood</i> , 2016, 128, 1814-1820.	1.4	75
27	Sporadic occurrence of non-diagnosed IgG4-related disease in lymphoma patients with a previous Sjögren's syndrome diagnosis. <i>Acta Oncologica</i> , 2016, 55, 1139-1144.	1.8	4
28	Association between HLA-A1 and -A2 types and Epstein-Barr virus status of post-transplant lymphoproliferative disorder. <i>Leukemia and Lymphoma</i> , 2016, 57, 2351-2358.	1.3	15
29	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 3026-3034.	1.4	168
30	15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. <i>British Journal of Haematology</i> , 2016, 175, 410-418.	2.5	170
31	miR-18b overexpression identifies mantle cell lymphoma patients with poor outcome and improves the MIPI-B prognosticator. <i>Blood</i> , 2015, 125, 2669-2677.	1.4	44
32	Leukemia and Myelodysplastic Syndrome in Granulomatosis with Polyangiitis: Subtypes, Clinical Characteristics, and Outcome. <i>Journal of Rheumatology</i> , 2015, 42, 690-694.	2.0	6
33	Molecular Evidence for Antigen Drive in the Natural History of Mantle Cell Lymphoma. <i>American Journal of Pathology</i> , 2015, 185, 1740-1748.	3.8	13
34	Two courses of four weekly infusions of rituximab with or without interferon- γ 2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2015, 56, 2598-2607.	1.3	24
35	Alterations of the CD58 gene in classical Hodgkin lymphoma. <i>Genes Chromosomes and Cancer</i> , 2015, 54, 638-645.	2.8	36
36	Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. <i>Blood</i> , 2014, 123, 2953-2959.	1.4	90

#	ARTICLE	IF	CITATIONS
37	Human Cytomegalovirus Tegument Protein pp65 Is Detected in All Intra- and Extra-Axial Brain Tumours Independent of the Tumour Type or Grade. PLoS ONE, 2014, 9, e108861.	2.5	37
38	The Transcriptomic and Proteomic Landscapes of Bone Marrow and Secondary Lymphoid Tissues. PLoS ONE, 2014, 9, e115911.	2.5	13
39	Diagnostic Tumor Mirna Profiling Predicts Molecular Relapse in Mantle Cell Lymphoma Patients Prospectively Followed for Minimal Residual Disease. Results from the Nordic MCL2-3 Trials. Blood, 2014, 124, 2994-2994.	1.4	0
40	A5.27â€¦Ro52 Expression is a Prognostic Factor for Survival in B Cell Lymphoma. Annals of the Rheumatic Diseases, 2013, 72, A40.2-A40.	0.9	0
41	Error in a study of the outcome of mantle cell lymphoma: Nordic MCL2 Trial Update: 6-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+Autologous stem-cell support: still very long survival but. British Journal of Haematology, 2012, 158, 815-816.	2.5	1
42	Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+Autologous stem-cell support: still very long survival but late relapses do occur. British Journal of Haematology, 2012, 158, 355-362.	2.5	241
43	Nordic MCL3 Study: Zevalin Combined with High-Dose Chemotherapy Followed by Autologous Stem Cell Support As Late Intensification for Mantle Cell Lymphoma (MCL) Patients & 66 Years Not in CR After Induction Chemoimmunotherapy: No Benefit of Zevalin. Blood, 2012, 120, 747-747.	1.4	3
44	Rituximab (R) in Combination with Interferon-a2a (IFN) Versus Single R in Patients with Follicular or Other CD20+ Low-Grade (indolent) Lymphoma. Final Results From a Randomized Phase III Study From the Nordic Lymphoma Group. Blood, 2012, 120, 794-794.	1.4	1
45	MYC + Diffuse Large B Cell Lymphomas (DLBCL) Treated in Randomized Prospective Salvage Therapy, RICE or RDHAP Followed by BEAM Plus Autologous Stem Cell Transplantation (ASCT). A BioCORAL Report. Blood, 2011, 118, 594-594.	1.4	0
46	The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood, 2010, 115, 1530-1533.	1.4	167
47	R-CHOEP-14 - 6 Followed by Systemic CNS Prophylaxis for Diffuse Large B-Cell Lymphoma/Follicular Lymphoma Grade 3 with Age Adjusted IPI Score 2-3: Final Results of a Nordic Lymphoma Group Phase 2 Study Including 156 Patients Aged 18-65 Years.. Blood, 2010, 116, 2805-2805.	1.4	2
48	Intensive Induction Chemotherapy Followed by Autologous Stem Cell Transplantation (ASCT) In Patients with Enteropathy-Associated T-Cell Lymphoma: a Prospective Study by the Nordic Lymphoma Group (NLG-T01). Blood, 2010, 116, 3565-3565.	1.4	4
49	Favorable Outcome In ALK-Negative Anaplastic Large-Cell Lymphoma Following Intensive Induction Chemotherapy and Autologous Stem Cell Transplantation (ASCT): a Prospective Study by the Nordic Lymphoma Group (NLG-T01). Blood, 2010, 116, 3566-3566.	1.4	5
50	Prognostic Impact of Germinal Center (GC)/ Activated B-Cell (ABC) Classification Analysed by Immunochemistry, FISH Analysis and GEP, In Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The Bio-CORAL Study. Blood, 2010, 116, 993-993.	1.4	8
51	Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood, 2008, 112, 2687-2693.	1.4	571
52	Lymphomas in Rheumatoid Arthritis Patients Treated with Anti-TNF Therapy: A Report from the Swedish Biologics Register (ARTIS) and the ARTIS Study Group 1998-2006. Blood, 2008, 112, 3754-3754.	1.4	0
53	Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. Arthritis and Rheumatism, 2006, 54, 692-701.	6.7	776
54	A comparative study of proliferation-associated parameters in b-cell non-hodgkin lymphoma. Hematological Oncology, 2006, 9, 287-298.	1.7	15

#	ARTICLE	IF	CITATIONS
55	Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis. <i>Modern Pathology</i> , 2005, 18, 1113-1120.	5.5	185
56	Epstein-Barr Virus Distribution in Hodgkin's Disease in an Unselected Swedish Population. <i>Acta Oncologica</i> , 1999, 38, 425-429.	1.8	57
57	The potential of human mast cell progenitors to differentiate into mature mast cells remains after prolonged culture with flt3 ligand, interleukin-3 or granulocyte-macrophage colony stimulating factor. <i>British Journal of Haematology</i> , 1999, 104, 516-522.	2.5	9
58	Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin's lymphomas. <i>European Journal of Haematology</i> , 1999, 62, 202-209.	2.2	9
59	Alterations of the Immunoglobulin Heavy Chain Locus in Progressive B-cell Lymphomas. <i>Acta Oncologica</i> , 1998, 37, 193-200.	1.8	4
60	[¹⁸ F] FDG PET in Gastric Non-Hodgkin's Lymphoma. <i>Acta Oncologica</i> , 1997, 36, 577-584.	1.8	38
61	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. , 1997, 71, 510-516.		25
62	Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. , 1997, 72, 394-397.		35
63	Patients suffering from both Hodgkin's disease and non-Hodgkin's lymphoma: A clinico-pathological and immuno-histochemical population-based study of 32 patients. <i>International Journal of Cancer</i> , 1997, 71, 510-516.	5.1	1
64	Detection of tumor-specific cytotoxic drug activity IN VITRO using the fluorometric microculture cytotoxicity assay and primary cultures of tumor cells from patients. <i>International Journal of Cancer</i> , 1994, 56, 715-720.	5.1	71
65	Diagnostics of Malignant Lymphomas with Ultrasound Guided 1.2 MM Biopsy-Gun. <i>Acta Oncologica</i> , 1994, 33, 33-37.	1.8	11
66	Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. <i>Hematological Oncology</i> , 1993, 11, 187-193.	1.7	79
67	Lymphoma Incidence in a Swedish County During 1969-1987. <i>Acta Oncologica</i> , 1992, 31, 275-282.	1.8	30
68	Characterization of A U-937 subline which can be induced to differentiate in serum-free medium. <i>International Journal of Cancer</i> , 1992, 50, 153-160.	5.1	13
69	Prognostic significance of flow cytometry studies in B-cell non-hodgkin lymphoma. <i>Hematological Oncology</i> , 1990, 8, 1-12.	1.7	47
70	Immunophenotype analysis of B-CLL lymphoma and immunocytoma. <i>Apmis</i> , 1989, 97, 1025-1032.	2.0	5
71	Primarily asymptomatic low-grade non-Hodgkin lymphomas: Prediction of symptom-free survival and total survival. <i>European Journal of Haematology</i> , 1989, 43, 332-338.	2.2	14
72	Prognostic relevance of serum markers in relation to histopathology, stage and initial symptoms in advanced low-grade non-Hodgkin lymphomas. <i>European Journal of Haematology</i> , 1988, 40, 289-298.	2.2	22

#	ARTICLE	IF	CITATIONS
73	IgE-producing low-grade non-Hodgkin lymphoma. <i>European Journal of Haematology</i> , 1988, 41, 388-395.	2.2	1
74	Monocytic origin of the human hematopoietic cell line U-937 and its convertibility to macrophages evidenced by isoenzyme mapping. <i>International Journal of Cancer</i> , 1983, 31, 181-186.	5.1	63
75	Phenotypic and cytogenetic characteristics of a new Epstein-Barr virus negative cell line (SKW 4) derived from a B-cell lymphoma. <i>Hematological Oncology</i> , 1983, 1, 277-295.	1.7	11
76	Lysis of fresh human B-lymphocyte-derived leukemia cells by interferon-activated natural killer (NK) cells. <i>International Journal of Cancer</i> , 1982, 29, 1-7.	5.1	36
77	Lysis of human B-lymphocyte-derived lymphoma/leukemia cells of established cell lines by interferon-activated natural killer (NK) cells. <i>International Journal of Cancer</i> , 1981, 28, 459-468.	5.1	16
78	Pernicious Anaemia in Association with Argyrophil (Sevier-Munger) Gastric Carcinoid. <i>Scandinavian Journal of Haematology</i> , 1979, 23, 415-420.	0.0	17
79	Establishment and characterization of a human histiocytic lymphoma cell line (U-937). <i>International Journal of Cancer</i> , 1976, 17, 565-577.	5.1	2,348
80	Establishment and characteristics of two unique cell lines from patients with lymphosarcoma. <i>International Journal of Cancer</i> , 1974, 13, 808-823.	5.1	163